Vivo Ventures is a life-sciences focused venture capital firm formed in 1996 with over $650M under management. Vivo Ventures is currently making investments from its $275M sixth fund into promising biotechnology and life science companies.

With over 90 years of scientific and operational expertise in biotechnology, Vivo makes investment decisions for the Funds and helps its portfolio companies develop corporate strategy, arrange licensing agreements and strategic alliances, recruit key management personnel, and acquire new products and technology to accelerate growth. Its current portfolio includes more than 60 private and public biotechnology companies in the areas of biopharmaceuticals, specialty pharmaceuticals, and medical devices.

China Kanghui Holdings Announces Pricing of Initial Public Offering
Changzhou, China - August 10, 2010

FDA Approves Sagent Pharmaceuticals, Inc.'s Heparin Sodium Injection, USP
Schaumburg, IL - July 1, 2010

Vicept Therapeutics Secures $10 Million to Complete Series A Funding; Company to Develop Lead Product for Rosacea and Other Topical Agents for the Treatment of Skin Disorders
Malvern, PA – June 30, 2010

Dynavax Raises $44 Million Through Public Offering of Common Stock and Warrants
Berkeley, CA - April 13, 2010

Sagent Pharmaceuticals Raises $40 Million in Two Tranches of a Series B Financing
Schaumburg, IL - April 8, 2010

Merz to Acquire BioForm Medical
Frankfurt, Germany & San Mateo, CA -
January 4, 2010